SCHEMBL19981575

SCHEMBL19981575

COP(C)(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 2/20 0.45
GFER P55789 1/20 0.45
CHRNA7 P36544 2/20 0.44
ALDH1A1 P00352 3/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
SIGMAR1 Q99720 2/20 0.42
DRD2 P14416 1/20 0.42
MAPK1 P28482 3/20 0.42
CYP3A4 P08684 2/20 0.42
ALOX15 P16050 1/20 0.42
CHRNB2 P17787 1/20 0.42
NFKB1 P19838 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15443824 0.82 CHRNA7 (0.49) MAPTNPSR1TSHRGFERCHRNA7
SCHEMBL15871579 0.81 GFER (0.44) MAPTNPSR1TSHRGFERCHRNA7
SCHEMBL25775999 0.77
SCHEMBL20019684 0.75 MAPT (0.47) MAPTALDH1A1PKMCYP3A4KMT2A
SCHEMBL164538 0.72 LMNA (0.67) MAPTTSHRCHRNA7ALDH1A1SIGMAR1
SCHEMBL16924853 0.72 LMNA (0.67) MAPTTSHRCHRNA7ALDH1A1SIGMAR1
SCHEMBL576814 0.72 LMNA (0.67) MAPTTSHRCHRNA7ALDH1A1SIGMAR1
SCHEMBL576454 0.72 LMNA (0.67) MAPTTSHRCHRNA7ALDH1A1SIGMAR1
SCHEMBL385012 0.72
SCHEMBL14995047 0.71 TSHR (0.47) MAPTNPSR1TSHRGFERCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788487-B1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS INC (US) 2018-04-04 EP disclosed
EP-2788488-B1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS INC (US) 2018-03-21 EP disclosed